Bidding 21-25 May 2026, price band ₹132–139, lot 1000 shares.
GMP last updated: 29 May 2026, 9:36 AM IST
| Date | GMP (₹) | Est. Listing Price (₹) | Est. Listing Gain |
|---|---|---|---|
| 28 May | -₹9 | ₹130 | -6.47% |
| 27 May | -₹9 | ₹130 | -6.47% |
| 26 May | -₹6 | ₹133 | -4.32% |
| 25 May | -₹6 | ₹133 | -4.32% |
| 24 May | ₹0 | ₹139 | 0.00% |
| 23 May | ₹0 | ₹139 | 0.00% |
| 22 May | ₹0 | ₹139 | 0.00% |
| 21 May | ₹0 | ₹139 | 0.00% |
| 20 May | ₹4 | ₹143 | 2.52% |
| 19 May | ₹0 | ₹139 | 0.00% |
| 18 May | ₹0 | ₹139 | 0.00% |
| 17 May | ₹0 | ₹139 | 0.00% |
| 16 May | ₹0 | ₹139 | 0.00% |
After allotment
| Category | Times | Est. Allotment Chances* |
|---|---|---|
| HNIs (Total) | 1.3 | 76.9% |
| bHNI | 0.86 | 100% |
| sHNI | 2.19 | 45.7% |
| QIBs | 15.94🔥 | - |
| Retail | 2.91 | 34.4% |
| Total | 2.26 | - |
*Rough estimate: 1 ÷ times subscribed. Retail and HNI allotment is by lottery, so actual odds depend on the number of applications.
Bio Medica Laboratories Limited is a pharmaceutical company engaged in the manufacturing of pharmaceutical parenteral formulations. The company manufactures generic injectable drugs, including liquid injections and dry powder injections, for both human and veterinary use. Its products are offered in single-dose and multi-dose formats to address a range of medical requirements. The company follows a business-to-business (B2B) model and primarily generates revenue through contract manufacturing arrangements with pharmaceutical companies. Under this model, Bio Medica manufactures formulations based on customer specifications, while the client company markets the products under its own brand name or as a technical collaborator. The company operates manufacturing facilities in Indore, Madhya Pradesh, and focuses on supplying formulations to other pharmaceutical businesses rather than directly selling to end consumers.